These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 11576882)

  • 1. N(epsilon)-(carboxymethyl)lysine levels in patients with type 2 diabetes: role of renal function.
    Wagner Z; Wittmann I; Mazák I; Schinzel R; Heidland A; Kientsch-Engel R; Nagy J
    Am J Kidney Dis; 2001 Oct; 38(4):785-91. PubMed ID: 11576882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes.
    Miura J; Yamagishi Si; Uchigata Y; Takeuchi M; Yamamoto H; Makita Z; Iwamoto Y
    J Diabetes Complications; 2003; 17(1):16-21. PubMed ID: 12505751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients.
    Wautier MP; Massin P; Guillausseau PJ; Huijberts M; Levy B; Boulanger E; Laloi-Michelin M; Wautier JL
    Diabetes Metab; 2003 Feb; 29(1):44-52. PubMed ID: 12629447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and nepsilon-(carboxymethyl)lysine ELISA.
    Galler A; Müller G; Schinzel R; Kratzsch J; Kiess W; Münch G
    Diabetes Care; 2003 Sep; 26(9):2609-15. PubMed ID: 12941727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension.
    Busch M; Franke S; Wolf G; Brandstädt A; Ott U; Gerth J; Hunsicker LG; Stein G;
    Am J Kidney Dis; 2006 Oct; 48(4):571-9. PubMed ID: 16997053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between blood levels of N-carboxymethyl-lysine and pentosidine and the severity of microangiopathy in type 2 diabetes.
    Hirata K; Kubo K
    Endocr J; 2004 Dec; 51(6):537-44. PubMed ID: 15644571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function.
    Gohda T; Tanimoto M; Moon JY; Gotoh H; Aoki T; Matsumoto M; Shibata T; Ohsawa I; Funabiki K; Tomino Y
    Diabetes Res Clin Pract; 2008 Aug; 81(2):196-201. PubMed ID: 18550199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocotrienol-Rich Vitamin E from Palm Oil (Tocovid) and Its Effects in Diabetes and Diabetic Nephropathy: A Pilot Phase II Clinical Trial.
    Tan SMQ; Chiew Y; Ahmad B; Kadir KA
    Nutrients; 2018 Sep; 10(9):. PubMed ID: 30227659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of N-ε- carboxy methyl lysine, advanced glycation end products and reactive oxygen species for the development of nonproliferative and proliferative retinopathy in type 2 diabetes mellitus.
    Choudhuri S; Dutta D; Sen A; Chowdhury IH; Mitra B; Mondal LK; Saha A; Bhadhuri G; Bhattacharya B
    Mol Vis; 2013; 19():100-13. PubMed ID: 23378723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific fluorescence assay for advanced glycation end products in blood and urine of diabetic patients.
    Yanagisawa K; Makita Z; Shiroshita K; Ueda T; Fusegawa T; Kuwajima S; Takeuchi M; Koike T
    Metabolism; 1998 Nov; 47(11):1348-53. PubMed ID: 9826211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pentosidine and N-carboxymethyl-lysine: biomarkers for type 2 diabetic retinopathy.
    Ghanem AA; Elewa A; Arafa LF
    Eur J Ophthalmol; 2011; 21(1):48-54. PubMed ID: 20544678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased serum levels of pentosidine, but not carboxymethyl lysine, in type 2 diabetes without obvious diabetic nephropathy.
    Daimon M; Ono Y; Saito T; Yamaguchi H; Hirata A; Ohnuma H; Igarashi M; Eguchi H; Manaka H; Kato T
    Diabetes Care; 1999 May; 22(5):877-8. PubMed ID: 10332715
    [No Abstract]   [Full Text] [Related]  

  • 13. Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients.
    Takeuchi M; Makita Z; Yanagisawa K; Kameda Y; Koike T
    Mol Med; 1999 Jun; 5(6):393-405. PubMed ID: 10415164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased levels of N(epsilon)-(carboxymethyl)lysine and N(epsilon)-(carboxyethyl)lysine in type 1 diabetic patients with impaired renal function: correlation with markers of endothelial dysfunction.
    Lieuw-A-Fa ML; van Hinsbergh VW; Teerlink T; Barto R; Twisk J; Stehouwer CD; Schalkwijk CG
    Nephrol Dial Transplant; 2004 Mar; 19(3):631-6. PubMed ID: 14767019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary excretion of advanced glycation endproducts in patients with type 2 diabetes and various stages of proteinuria.
    Turk N; Mornar A; Mrzljak V; Turk Z
    Diabetes Metab; 2004 Apr; 30(2):187-92. PubMed ID: 15223992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
    Busch M; Franke S; Wolf G; Rohde RD; Stein G;
    Nephron Clin Pract; 2008; 108(4):c291-7. PubMed ID: 18434751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of low molecular weight advanced glycation end products in diabetic subjects.
    Sharp PS; Rainbow S; Mukherjee S
    Diabet Med; 2003 Jul; 20(7):575-9. PubMed ID: 12823240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated serum levels of N(epsilon)-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema.
    Boehm BO; Schilling S; Rosinger S; Lang GE; Lang GK; Kientsch-Engel R; Stahl P
    Diabetologia; 2004 Aug; 47(8):1376-9. PubMed ID: 15258735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dietary intake associated with serum versus urinary carboxymethyl-lysine, a major advanced glycation end product, in adults: the Energetics Study.
    Semba RD; Ang A; Talegawkar S; Crasto C; Dalal M; Jardack P; Traber MG; Ferrucci L; Arab L
    Eur J Clin Nutr; 2012 Jan; 66(1):3-9. PubMed ID: 21792213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma levels of pentosidine in diabetic patients: an advanced glycation end product.
    Sugiyama S; Miyata T; Ueda Y; Tanaka H; Maeda K; Kawashima S; Van Ypersele de Strihou C; Kurokawa K
    J Am Soc Nephrol; 1998 Sep; 9(9):1681-8. PubMed ID: 9727377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.